This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 18-25 May 2024 and includes updates on respiratory virus epidemiology in the EU/EEA, influenza, avian influenza, and cholera.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 11-17 May 2024 and includes updates on invasive meningococcal disease, an overview of respiratory virus epidemiology in the EU/EEA, cholera and measles.
For 2022, 28 European Union/European Economic Area (EU/EEA) countries reported data on Crimean-Congo haemorrhagic fever (CCHF) and two countries reported a total of four cases.
Additional cases of Crimean-Congo haemorrhagic fever (CCHF), a potentially life threatening tick-borne viral disease, have been reported in the EU/EEA, according to new data published by ECDC. Experts have warned of an increased risk of transmission on the continent.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 5–11 May 2024 and includes updates on cholera and western equine encephalitis.
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 28 April - 4 May 2024 and includes updates on cholera, MERS-CoV, SARS-CoV-2, an overview of respiratory virus epidemiology in the EU/EEA, highly pathogenic avian influenza A(H5N1) in cattle and a related human case, Crimean-Congo haemorrhagic fever, and Lassa fever.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21–27 April 2024 and includes updates on respiratory virus epidemiology in the EU/EEA, West Nile virus, SARS-CoV-2 variant classification and Cholera.
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.